Gerald Möller

Sep 14, 2015

Ayoxxa Biosystems said that Gerald Möller has joined its board as an independent director and as its chairman. He will guide the firm's expansion from life science research into disease-specific applications for Ayoxxa's Lunaris multiplexing technology. Möller has 40 years of management experience in the diagnostic and pharmaceutical industries and was most recently an investment advisor to HMB Partners. He held senior management positions at Boehringer Mannheim from 1975 to 1998 and became CEO of the worldwide operating group in 1995. He was also a board member at Illumina before leaving in May. He currently is chairman of Morphosys.

Gerald Möller

Grail Q1 Revenues up 19 Percent Driven by Clinical Test Growth

Seer Q1 Revenues Rise 35 Percent

Biodesix Q1 Revenues up 21 Percent as Firm Slashes Full-Year Guidance on Sales Restructuring

MantaBio Nabs $2.5M in Seed Funding to Develop Microbial Detection Platform for Biopharma

Socioeconomic Factors, Not Genetic Ancestry, Linked to All-Cause Mortality in Black Americans